Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy Trials
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Crispr Therapeutics AG (NASDAQ:CRSP) have announced new data from Phase 1/2 clinical trials evaluating CTX001 in beta-thalassemia and…